MRNA Moderna Inc
- Stocks
- Healthcare
- NASDAQ: MRNA
Price (delayed)
$25.74
Market cap
$10.01B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.53
Enterprise value
$9.43B
Relative Growth:
Rel. Growth:
34
Relative Strength:
Rel. Strength:
12
Relative Valuation:
Rel. Valuation:
17
Relative Profitability:
Rel. Profitability:
32
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert
Highlights
The net income has soared by 51% YoY and by 14% from the previous quarter
The company's EPS has surged by 51% YoY and by 14% QoQ
The gross margin has soared by 59% YoY but it has contracted by 3% from the previous quarter
MRNA's revenue is down by 39% year-on-year and by 3.1% since the previous quarter
The equity is down by 20% YoY and by 7% QoQ
Key stats
What are the main financial stats of MRNA
Market
Valuations
Earnings
Shares outstanding
389.08M
Market cap
$10.01B
Enterprise value
$9.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.06
Price to sales (P/S)
3.24
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
Revenue
$3.08B
Gross profit
$1.62B
Operating income
-$3.27B
Net income
-$2.9B
EBIT
-$2.95B
EBITDA
-$2.74B
Free cash flow
-$3.5B
Per share
Balance sheet
Liquidity
EPS
-$7.53
EPS diluted
-$7.53
Free cash flow per share
-$9.02
Book value per share
$24.3
Revenue per share
$7.93
TBVPS
$30.95
Total assets
$12.01B
Total liabilities
$2.61B
Debt
$698M
Equity
$9.4B
Working capital
$4.6B
Debt to equity
0.07
Current ratio
3.93
Quick ratio
3.29
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
-88.9%
Gross margin
52.5%
Net margin
-94.3%
Operating margin
-106.3%
Return on assets
-21.2%
Return on equity
-27.5%
Return on invested capital
-26.8%
Return on capital employed
-28.2%
Return on sales
-95.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
9.25%
1 week
-8.53%
1 month
-6.54%
1 year
-50.32%
YTD
-38.1%
QTD
-0.35%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$3.08B
Gross profit
$1.62B
Operating income
-$3.27B
Net income
-$2.9B
Gross margin
52.5%
Net margin
-94.3%
The gross margin has soared by 59% YoY but it has contracted by 3% from the previous quarter
The net income has soared by 51% YoY and by 14% from the previous quarter
MRNA's revenue is down by 39% year-on-year and by 3.1% since the previous quarter
The operating income has grown by 29% YoY and by 12% from the previous quarter
Price vs fundamentals
How does MRNA's price correlate with its fundamentals
Growth
What is Moderna's growth rate over time
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
1.06
P/S
3.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
The company's EPS has surged by 51% YoY and by 14% QoQ
MRNA's P/B is 82% below its 5-year quarterly average of 5.5 and 35% below its last 4 quarters average of 1.5
The equity is down by 20% YoY and by 7% QoQ
The stock's P/S is 65% below its 5-year quarterly average of 8.6 and 29% below its last 4 quarters average of 4.2
MRNA's revenue is down by 39% year-on-year and by 3.1% since the previous quarter
Efficiency
How efficient is Moderna business performance
MRNA's return on equity is up by 39% year-on-year and by 9% since the previous quarter
Moderna's ROA has increased by 37% YoY and by 8% from the previous quarter
The ROIC has grown by 19% YoY and by 9% from the previous quarter
The company's return on sales fell by 12% YoY but it rose by 11% QoQ
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
Moderna's total liabilities has decreased by 34% YoY
Moderna's total assets has decreased by 23% YoY and by 5% from the previous quarter
The debt is 93% smaller than the equity
The debt has declined by 44% year-on-year
The company's debt to equity fell by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.